Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q2 2020 Earnings Conference Call - Final Transcript

Aug 06, 2020 • 04:30 pm ET

Previous

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q2 2020 Earnings Conference Call - Final Transcript

Share
Close

Loading Event

Loading Transcript

Presentation
Operator
Operator

Good day, ladies and gentlemen, and welcome to Quarter 2 2020 Xenon Pharmaceuticals Incorporated Earnings Conference Call. [Operator Instructions]

I would now like to turn the call over to Ms. Jodi Regts. Ma'am, the floor is yours.

Executive
Jodi Regts

Thank you. Good afternoon. Thanks, everyone, for joining us on our call and webcast to discuss our second quarter 2020 financial and operating results. Joining me on today's call are Dr. Simon Pimstone, Xenon's Chief Executive Officer; and Ian Mortimer, Xenon's President and Chief Financial Officer. Following this introduction, Simon will give an overview of Xenon's clinical programs, and then Ian will provide some high-level financial commentary. After that, we will open up the call to your questions.

Please be advised that during this call, we will make a number of statements that are forward-looking, including statements regarding the anticipated impact and timing of the COVID-19 pandemic on our business, research and clinical development plans and time lines and results of operations, the timing of and results from clinical trials and preclinical development activities, including those related to XEN496, XEN1101, XEN007 and other proprietary products and those related to NBI921352, FX301 and other partnered product candidates; the potential efficacy, safety profile, future development plans, addressable market, regulatory success and commercial potential of our proprietary and partnered product candidates; the anticipated timing IND or IND equivalent submissions and the initiation of future clinical trials for our proprietary products and those related to other partnered candidates; the efficacy of our clinical trial designs, our ability to successfully develop and achieve milestones in our proprietary programs, the timing and results of our interactions with regulators, the potential to advance certain of our product candidates directly into Phase II or later-stage clinical trials, the timing and anticipated enrollment in our clinical trials, the progress and potential ongoing development programs, the potential receipt of milestone payments and royalties from our collaborators, our expectation of having sufficient cash to fund operations into 2022 and the timing of potential publication or presentation of future clinical data.

Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond our control, including the risks and uncertainties described from time to time in our SEC filings. Our results may differ materially from those projected on today's call. We undertake no obligation to publicly update any forward-looking statement. Today's press release summarizing the results of Xenon's second quarter of 2020 and the accompanying quarterly report on Form 10-Q are available under the Investors section of our website at www.xenon-pharma.com and filed with the SEC and on SEDAR.

Now I would like to turn the call over to Simon.

Executive
Simon Pimstone

Thank you, Jodi, and good afternoon, everyone, and thanks for joining us today. I hope everyone is staying well. Here at Xenon, we continue to manage well as we respond to the global impacts of the COVID-19 pandemic, and importantly, also have the cash runway to support our near-term business objectives. We're looking forward to several key milestone events over the next 12 months,